ArticleBreast cancer research : BCR2026

CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer.

Yu Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.